Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Heptares Will Work With AstraZeneca
by Ann M. Thayer
June 6, 2011
| A version of this story appeared in
Volume 89, Issue 23
AstraZeneca and U.K.-based Heptares Therapeutics will collaborate on the discovery and development of compounds targeting G-protein-coupled receptors (GPCRs). Under the four-year deal, AstraZeneca will pay $6.25 million in cash plus research funding to Heptares in exchange for commercial rights to any resulting products. The partners will focus on GPCR targets—which are stabilized for investigation by Heptares’ technology—related to central nervous system, cardiovascular, metabolic, and inflammatory disorders.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter